Key result
Sitagliptin increases total fractional sodium excretion versus placebo after one month.
Why the study?
Does sitagliptin modulate fractional sodium excretion and renal and systemic hemodynamic function in patients with type 2 diabetes?
Population
32 patients with type 2 diabetes
Comparison
Sitagliptin vs Placebo
Design
RCT, randomized, double-blind
Follow-up
1 month
Authors
Loading...
Sitagliptin promotes distal tubular natriuresis without altering proximal reabsorption or renal hemodynamics; supports safe combination with SGLT2 inhibitors in type 2 diabetes and extends mechanistic data.
RCT (n=32)
double-blind
randomized
Does sitagliptin modulate fractional sodium excretion and renal and systemic hemodynamic function in patients with type 2 diabetes?
p-value: p=0.012
DPP-4 inhibition with sitagliptin promotes distal tubular natriuresis and increases intact SDF-1α1-67 without impairing renal hemodynamics in patients with type 2 diabetes.
Lovshin et al. (2017) conducted an RCT in type 2 diabetes (n=32). sitagliptin vs. placebo was evaluated on total fractional sodium excretion (p=0.012). Sitagliptin significantly increased total fractional sodium excretion compared with placebo after 1 month of treatment (P=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: